Download PDF
Thromb Haemost 2000; 84(03): 506-513
DOI: 10.1055/s-0037-1614052
Commentary
Schattauer GmbH

Reduction of von Willebrand Factor by Endothelial Cells

Lijuan Xie
1   From the Centre for Thrombosis and Vascular Research, School of Pathology, University of New South Wales and Department of Haematology, Prince of Wales Hospital, Sydney, NSW, Australia
,
Colin N. Chesterman
1   From the Centre for Thrombosis and Vascular Research, School of Pathology, University of New South Wales and Department of Haematology, Prince of Wales Hospital, Sydney, NSW, Australia
,
Philip J. Hogg
1   From the Centre for Thrombosis and Vascular Research, School of Pathology, University of New South Wales and Department of Haematology, Prince of Wales Hospital, Sydney, NSW, Australia
› Author AffiliationsThis study was supported by grants from the National Health and Medical Research Council of Australia, the National Heart Foundation of Australia, and an Infrastructure Grant from the NSW Health Department. The authors thank Dr. M. Berndt for the purified vWF, Dr. P. Warburton for TTP plasma and clinical details, Dr. A. Holmgren for the human recombinant thioredoxin and Dr. Vischer for the vWF propolypeptide monoclonal antibody, 3H4.
Further Information

Publication History

Received 16 December 1999

Accepted after resubmission 14 April 2000

Publication Date:
14 December 2017 (online)

    Permissions and Reprints

Summary

The haemostatic activity of plasma von Willebrand factor (vWF) is a function of multimer size. Only the large vWF multimers are effective in promoting platelet adhesion to a site of vascular injury. We observed that the conditioned medium of cultured human umbilical vein, human microvascular and bovine aortic endothelial cells contained an activity which reduced the average multimer size of plasma or purified vWF. The average multimer size of vWF produced endogenously by human umbilical vein endothelial cells was similarly reduced following secretion. The reducing activity was ablated by pre-treatment with heat or the thiol blocking agents, iodoacetamide, N-ethylmaleimide or E-64, but not by a range of specific serine-, cysteine-, aspartic-, or metalloproteinase inhibitors. Reduction in vWF multimer size was associated with formation of new thiols in vWF and there was no evidence for additional proteolytic processing of vWF. The reducing activity was associated with a protein with an anionic pI that binds heparin and contains reactive thiol(s). These results suggested that the interchain disulfide bonds that link the vWF homodimers near the N-termini were being reduced by a vWF reductase secreted by endothelial cells. In support of this hypothesis, incubation of vWF with the protein reductants, protein disulfide isomerase and thioredoxin, resulted in formation of new thiols in vWF and reduction in the average multimer size of vWF. These findings may have consequences for control of vWF haemostatic activity.

Abbreviations: BAEC, bovine aortic endothelial cell; BSA, bovine serum albumin; cm, conditioned medium; GSH, reduced glutathione; HUVEC, human umbilical vein endothelial cell; HDMVEC, human dermal microvascular endothelial cell; IAM, iodoacetamide; MPB, 3-(N-maleimidylpropionyl)biocytin; NEM, N-ethylmaleimide; PDI, protein disulfide isomerase; PVDF, polyvinylidene difluoride; vWF, von Willebrand factor.

Key words

von Willebrand factor - endothelial cell - reductase
 

  • References

  • 1 Sadler JE. Biochemistry and genetics of von Willebrand factor. Ann Rev Biochem 1998; 67: 395-424.
    CrossrefPubMedGoogle Scholar
  • 2 Counts RB, Paskell SL, Elgee SK. Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor. J Clin Invest 1978; 62: 702-9.
    CrossrefPubMedGoogle Scholar
  • 3 Perret BA, Furlan M, Beck EA. Studies on factor VIII-related protein. II. Estimation of molecular size differences between factor VIII oligomers. Biochim Biophys Acta 1979; 578: 164-74.
    CrossrefPubMedGoogle Scholar
  • 4 Wagner DD, Lawrence SO, Ohlsson-Wilhelm BM, Fay PJ, Marder VJ. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood 1987; 69: 27-32.
    PubMedGoogle Scholar
  • 5 Furlan M. von Willebrand factor: molecular size and functional activity. Ann Hematol 1996; 72: 341-8.
    CrossrefPubMedGoogle Scholar
  • 6 Furlan M, Perret BA, Beck EA. Studies on factor VIII-related protein. III. Size distribution and carbohydrate content of human and bovine factor VIII. Biochim Biophys Acta 1979; 579: 325-33.
    CrossrefPubMedGoogle Scholar
  • 7 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stressinduced platelet aggregation. J Clin Invest 1989; 78: 1456-61.
    PubMedGoogle Scholar
  • 8 Moake JL. Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Sem Hematol 1997; 34: 83-9.
    PubMedGoogle Scholar
  • 9 Field SL, Khachigian LM, Sleigh MJ, Yang G, Hogg PJ, Chesterman CN. Extracellular matrix as a source of mitogenically active platelet-derived growth factor. J Cell Physiol 1996; 168: 322-32.
    CrossrefPubMedGoogle Scholar
  • 10 Jackson CJ, Garbett PK, Nissen B, Schreiber LJ. Binding of human endothelium to Ulex europaeus I-coated Dynabeads: application to the isolation of microvascular endothelium. J Cell Sci 1990; 96: 257-62.
    PubMedGoogle Scholar
  • 11 Hogg PJ, Öhlin A-K, Stenflo J. Identification of structural domains in protein C involved in its interaction with thrombin-thrombomodulin on the surface of endothelial cells. J Biol Chem 1992; 267: 703-6.
    PubMedGoogle Scholar
  • 12 Ruggeri ZM, Zimmerman TS. Variant von Willebrand's disease: Characterization of two subtypes by analysis of multimer composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-25.
    CrossrefPubMedGoogle Scholar
  • 13 Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between Type I and Type II, von Willebrand’s disease. Blood Coag Fibrinol 1991; 02: 285-91.
    CrossrefPubMedGoogle Scholar
  • 14 Booth WJ, Furby FH, Berndt MC, Castaldi PA. Factor VIII/von Willebrand factor has potent lectin activity. Biochem Biophys Res Commun 1984; 118: 495-501.
    CrossrefPubMedGoogle Scholar
  • 15 Siekmann J, Turecek PL, Schwarz HP. The determination of von Willebrand factor activity by collagen binding assay. Haemophilia 1998; 04: 15-24.
    CrossrefPubMedGoogle Scholar
  • 16 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
    PubMedGoogle Scholar
  • 17 Hawkins HC, Freedman RB. The reactivities and ionization properties of the active-site dithiol groups of mammalian protein disulfide-isomerase. Biochem J 1991; 275: 335-9.
    CrossrefPubMedGoogle Scholar
  • 18 Freedman RB, Hirst TR, Tuitte MF. Protein disulfide isomerase: building bridges in protein folding. Trend Biochem Sci 1994; 19: 331-6.
    CrossrefPubMedGoogle Scholar
  • 19 Torchinski YM. Thiol and disulfide groups in proteins. Dixon HBF. ed. Consultants Bureau; New York: 1974: 24.
    Google Scholar
  • 20 Stathakis P, Fitzgerald M, Matthias LJ, Chesterman CN, Hogg PJ. Generation of angiostatin by reduction and proteolysis of plasmin: catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem 1997; 272: 20641-5.
    CrossrefPubMedGoogle Scholar
  • 21 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103.
    PubMedGoogle Scholar
  • 22 Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
    CrossrefPubMedGoogle Scholar
  • 23 Tsai H-M. Physiological cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-44.
    PubMedGoogle Scholar
  • 24 Dong Z, Thoma RS, Crimmins DL, McCourt DW, Tuley EA, Sadler JE. Disulfide bonds required to assemble functional von Willebrand factor multimers. J Biol Chem 1994; 269: 6753-8.
    PubMedGoogle Scholar
  • 25 Jiang XM, Fitzgerald M, Matthias LJ, Hogg PJ. Redox control of exofacial protein thiols/disulfides by protein disulfide isomerase. J Biol Chem 1999; 274: 2416-23.
    CrossrefPubMedGoogle Scholar
  • 26 Hirano N, Shibasaki F, Sakai R, Tanaka T, Nishida J, Yazaki Y, Takenawa T, Hirai H. Molecular cloning of the human glucose-regulated protein Erp57/GRP58, a thiol-dependent reductase: Identification of its secretory form and inducible expression by the oncogenic transformation. Eur J Biochem 1995; 234: 336-42.
    CrossrefPubMedGoogle Scholar
  • 27 Rosén A, Lundman P, Carlsson M, Bhavani K, Srinivasa BR, Kjellström G, Nilsson K, Holmgren A. A CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin. Int Immunol 1995; 07: 625-33.
    CrossrefPubMedGoogle Scholar
  • 28 Hessel B, Jörnvall H, Thorell L, Söderman S, Larsson U, Egberg N, Blombäck B, Holmgren A. Structure-function relationships of human factor VIII complex studied by thioredoxin dependent disulfide reduction. Thromb Res 1984; 35: 637-51.
    CrossrefPubMedGoogle Scholar
  • 29 Bannai S, Tsukeda H. The export of glutathione from human diploid cells in culture. J. Biol Chem 1979; 254: 3444-50.
    PubMedGoogle Scholar
  • 30 Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 1992; 200: 218-29.
    CrossrefPubMedGoogle Scholar
  • 31 Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci USA 1992; 89: 3531-5.
    CrossrefPubMedGoogle Scholar
  • 32 Vischer UM, Ingerslev J, Wollheim CB, Mestries J-C, Tsakiris DA, Haefeli WE, Kruithof EKO. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) levels. Thromb Haemost 1997; 77: 387-93.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Fay PJ, Chavin SI, Schroeder D, Young FE, Marder VJ. Purification and characterization of a highly purified human factor VIII consisting of a single type of polypeptide chain. Proc Natl Acad Sci USA 1982; 79: 7200-4.
    CrossrefPubMedGoogle Scholar
  • 34 Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci USA 1987; 84: 1955-9.
    CrossrefPubMedGoogle Scholar
  • 35 Takagi J, Sekiya F, Kasahara K, Inada Y, Saito Y. Inhibition of plateletcollagen interaction by propolypeptide of von Willebrand factor. J Biol Chem 1989; 264: 6017-20.
    PubMedGoogle Scholar
  • 36 Frangos JA, Moake JL, Nolasco L, Phillips MD, McIntire LV. Cryosupernatant regulates accumulation of unusually large vWF multimers from endothelial cells. Am J Physiol 1989; 256: H1635-44.
    PubMedGoogle Scholar
  • 37 Phillips MD, Moake JL, Nolasca L, Garcia R. Plasma von Willebrand factor processing activity functions like a disulfide bond reductase: reversible decrease of multimer size. Thromb Haemost 1993; 69: 1199.
    PubMedGoogle Scholar